Incentives And Risks From OTC Drug Monograph Revamp
By Albert Cacozza, Steven Gonzalez and Jenna McCarthy (May 29, 2020, 6:14 PM EDT) -- On March 27, President Donald Trump signed into law the Coronavirus Aid, Relief and Economic Security Act, also known as Phase 3 of the coronavirus stimulus legislation. Title III, Subtitle F of the CARES Act, a provision unrelated to the current coronavirus pandemic, is an overhaul to the over-the-counter drug monograph system in the U.S.
This article analyzes the five key provisions of the OTC monograph reform, with a particular focus on the first four:
An outline of the status of currently marketed OTC monograph drugs;
An administrative process by which the U.S. Food and Drug Administration will establish/amend a monograph...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!